SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.00+8.5%Dec 3 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (7245)10/27/2002 12:04:40 PM
From: Biomaven  Read Replies (2) of 52153
 
Miljenko,

At the recent UBS Warburg conference my recollection is that VRTX said they expected initiation by Aventis of the Phase IIB in RA and a Phase II in OA "in the next few months." They characterized the OA market as 40X the size of the RA market. They said they had gotten very good results in a standard animal model of OA, and the key driver for OA was safety.

Here are the conference archives by the way:

event.streamx.us

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News